Ferroptosis as a new therapeutic opportunity for nonviral liver disease
After removing semaglutide (Ozempic, Wegovy) from the drug shortage list in early 2025, the FDA stated that 503A and 503B facilities may no longer compound copies of semaglutide for general distribution
The team is personable, engaged, and quietly confident
The weight loss piece is honestly where it gets interesting though
This conversation, supported by genetic context, helps you start treatment with clearer expectations and a safer monitoring plan aligned to your individual risk profile
Filing an Ozempic or Wegovy Lawsuit: What Patients, Family Members and Lawyers Need to Know Individuals and families that have claims related to Ozempic or Wegovy should consult with a mass tort lawyer promptly